GCP
LCTX icon

GSA Capital Partners’s Lineage Cell Therapeutics LCTX Stock Holding History

GSA Capital Partners’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-185,061
Closed -$292K – 1973
2026
Q1 		$292K Sell
185,061
-145,920
-44% -$246K 0.02% 1266
2025
Q4 		$553K Sell
330,981
-339,875
-51% -$588K 0.05% 740
2025
Q3 		$1.13M Sell
670,856
-226,755
-25% -$268K 0.09% 322
2025
Q2 		$814K Sell
897,611
-39,281
-4% -$23.3K 0.06% 589
2025
Q1 		$423K Buy
936,892
+528,055
+129% +$310K 0.04% 911
2024
Q4 		$205K Buy
408,837
+315,805
+339% +$232K 0.02% 1403
2024
Q3 		$84K Buy
+93,032
New +$86.2K 0.01% 1503
2023
Q3 		– Sell
-13,196
Closed -$19K – 1724
2023
Q2 		$19K Buy
+13,196
New +$18.2K ﹤0.01% 1444
2022
Q4 		– Sell
-48,628
Closed -$55K – 1694
2022
Q3 		$55K Sell
48,628
-69,680
-59% -$102K 0.01% 1414
2022
Q2 		$187K Buy
118,308
+45,802
+63% +$60.4K 0.03% 1088
2022
Q1 		$112K Buy
+72,506
New +$113K 0.02% 1275
2021
Q2 		– Sell
-80,000
Closed -$188K – 1475
2021
Q1 		$188K Buy
+80,000
New +$192K 0.03% 925
2020
Q3 		– Sell
-15,191
Closed -$13K – 1323
2020
Q2 		$13K Buy
+15,191
New +$13.4K 0.01% 566
2018
Q1 		– Sell
-190,671
Closed -$359K – 1725
2017
Q4 		$359K Sell
190,671
-9,144
-5% -$20K 0.02% 1122
2017
Q3 		$496K Buy
199,815
+110,661
+124% +$274K 0.03% 972
2017
Q2 		$246K Buy
+89,154
New +$249K 0.02% 1401

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

GSA Capital Partners's LCTX Position: Q2 2026 in Review

GSA Capital Partners sold out of Lineage Cell Therapeutics (LCTX) in Q2 2026, closing a stake of 185,061 shares — an estimated $292K sold.

GSA Capital Partners first reported a position in LCTX in Q2 2017 and held it in 16 quarters. The position peaked at $1.13M in Q3 2025. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • GSA Capital Partners reported no remaining Lineage Cell Therapeutics position as of Q2 2026 after selling out during the quarter.
  • GSA Capital Partners sold 185,061 Lineage Cell Therapeutics shares in Q2 2026, an estimated $292K.
  • GSA Capital Partners first reported a position in Lineage Cell Therapeutics in Q2 2017 and held it in 16 quarters.
  • GSA Capital Partners's Lineage Cell Therapeutics position peaked at $1.13M in Q3 2025.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.